Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Revocation Determination 2015

Overview

The Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Revocation Determination 2015 was enacted to address the need for revocation of the Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Determination 2014. This revocation was necessitated by the incorporation of item number 73338 into the Health Insurance (Pathology Services Table) Regulation 2015, which was implemented by the Health Insurance Legislation Amendment (2015 Measures No. 1) Regulation 2015. This legislative instrument, issued under the authority of the Minister for Health, serves to update the Medicare Benefits Schedule (MBS) to reflect the current inclusion of pharmacogenetic testing for RAS mutations. The revocation was made to ensure that the relevant Medicare benefits could continue to be paid without the need for the 2014 Determination. The objective of this Determination was to streamline the legislative framework to accommodate the evolving medical landscape and ensure that patients have continued access to necessary healthcare services.

Scope and Application

The Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Revocation Determination 2015 applies to the Health Insurance Act 1973, specifically relating to the treatment of pharmacogenetic testing services for RAS (KRAS and NRAS) within the Medicare Benefits Schedule (MBS). This revocation aligns with the amendments made in the Health Insurance Legislation Amendment (2015 Measures No. 1) Regulation 2015, which incorporated the previously determined service into the Pathology Services Table from 1 September 2015. The Determination revokes the earlier Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Determination 2014, ensuring that the service is now appropriately listed in the Table without the need for additional determinations. The revocation takes effect from 1 September 2015, and it applies to all entities and individuals covered under the Health Insurance Act 1973, which is a Commonwealth Act extending its reach across Australia. There are no exclusions or exemptions specified in the Determination itself, but the Act and its regulations may contain provisions that govern eligibility and scope of coverage. The revocation of the 2014 Determination is a legislative instrument under the Legislative Instruments Act 2003, and no consultation was required as the change does not alter the current arrangements for patients or medical practitioners.

Key Provisions

The Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Revocation Determination 2015 (the Determination) revokes the Health Insurance (Pharmacogenetic Testing – RAS (KRAS and NRAS)) Determination 2014 (section 3). The primary purpose of the Determination is to remove a previously listed health service from the special category of services that are not otherwise listed in the Pathology Services Table but are still eligible for Medicare benefits (subsection 3C(1) of the Health Insurance Act 1973). This revocation becomes effective from 1 September 2015, aligning with the inclusion of the service in the Pathology Services Table through amendments in the Health Insurance Legislation Amendment (2015 Measures No. 1) Regulation 2015. The Determination imposes a clear obligation on the relevant parties to cease treating the previously specified pharmacogenetic testing service as if it were listed under the special provisions from the commencement date of the Determination. This means that as of 1 September 2015, the service will no longer be eligible for the special Medicare benefits that were previously applicable under the 2014 Determination. Instead, it will be subject to the general provisions of the Pathology Services Table, which includes the newly inserted item number 73338. In terms of consequences, the Determination itself does not outline specific offences, penalties, or other legal consequences for non-compliance. However, non-compliance with the changes in the Health Insurance Act 1973 and the associated regulations could result in legal repercussions. For instance, if a health service provider continues to claim Medicare benefits for the pharmacogenetic testing service under the old provisions after the Determination’s commencement, they may face penalties under the Medicare Benefits Scheme, including financial penalties or legal action for improper claims. The penalties for such actions are not detailed within the Determination but are governed by the broader Medicare framework, which can include fines and other civil or criminal penalties as stipulated in the Act. Overall, the Determination streamlines the administration of Medicare benefits by ensuring that the pharmacogenetic testing service is subject to the same rules as other services listed in the Pathology Services Table, thus simplifying the compliance requirements for both service providers and patients.